Cash Flow Statement

Capital Expenditures Cash from Financing Activities Cash from Investing Activities Cash from Operations Change in Cash Change in Intangibles Change in Working Capital Exchange Rate Effect Free Cash Flow Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Income Sales of Property, Plant and Equipment

Daily Values

Growth Metrics

Others

Ratios

Innate Pharma (IPHA) Asset Writedowns and Impairment (2020 - 2022)

Historic Asset Writedowns and Impairment for Innate Pharma (IPHA) over the last 2 years, with Q4 2022 value amounting to -$41830.1.